Literature DB >> 17873846

Synthesis of sulfonamides and evaluation of their histone deacetylase (HDAC) activity.

Seikwan Oh1, Hyung-In Moon, Il-Hong Son, Jae-Chul Jung, Mitchell A Avery.   

Abstract

A simple synthesis of sulfonamides 4-22 as novel histone deacetylase (HDAC) inhibitors is described. The key synthetic strategies involve N-sulfonylation of L-proline benzyl ester hydrochloride (2) and coupling reaction of N-sulfonyl chloride 3 with amines in high yields. It was found that several compounds showed good cellular potency with the most potent compound 20 exhibiting an IC50 = 2.8 microM in vitro.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17873846      PMCID： PMC6149482          DOI： 10.3390/12051125

Source DB:  PubMed          Journal:  Molecules        ISSN： 1420-3049            Impact factor:   4.411


  20 in total

1.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Authors:  Owen A O'Connor; Mark L Heaney; Lawrence Schwartz; Stacie Richardson; Robert Willim; Barbara MacGregor-Cortelli; Tracey Curly; Craig Moskowitz; Carol Portlock; Steven Horwitz; Andrew D Zelenetz; Stanley Frankel; Victoria Richon; Paul Marks; William K Kelly
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

2.  Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.

Authors:  Hwan Mook Kim; Kiho Lee; Bum Woo Park; Dong Kyu Ryu; Kangjeon Kim; Chang Woo Lee; Song-Kyu Park; Jung Whan Han; Hee Yoon Lee; Hyun Yong Lee; Gyoonhee Han
Journal:  Bioorg Med Chem Lett       Date:  2006-05-24       Impact factor: 2.823

3.  Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.

Authors:  Takayoshi Suzuki; Yuki Nagano; Akiyasu Kouketsu; Azusa Matsuura; Sakiko Maruyama; Mineko Kurotaki; Hidehiko Nakagawa; Naoki Miyata
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

Review 4.  Histone deacetylation in epigenetics: an attractive target for anticancer therapy.

Authors:  Antonello Mai; Silvio Massa; Dante Rotili; Ilaria Cerbara; Sergio Valente; Riccardo Pezzi; Silvia Simeoni; Rino Ragno
Journal:  Med Res Rev       Date:  2005-05       Impact factor: 12.944

5.  Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.

Authors:  Chihiro Shinji; Satoko Maeda; Keisuke Imai; Minoru Yoshida; Yuichi Hashimoto; Hiroyuki Miyachi
Journal:  Bioorg Med Chem       Date:  2006-07-31       Impact factor: 3.641

6.  Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.

Authors:  M Yoshida; M Kijima; M Akita; T Beppu
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

Review 7.  Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.

Authors:  T Owa; H Yoshino; K Yoshimatsu; T Nagasu
Journal:  Curr Med Chem       Date:  2001-10       Impact factor: 4.530

8.  Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.

Authors:  Gabriele Imre; Volker Gekeler; Astrid Leja; Thomas Beckers; Markus Boehm
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

9.  Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.

Authors:  Marielle Fournel; Marie-Claude Trachy-Bourget; P Theresa Yan; Ann Kalita; Claire Bonfils; Carole Beaulieu; Sylvie Frechette; Silvana Leit; Elie Abou-Khalil; Soon-Hyung Woo; Daniel Delorme; A Robert MacLeod; Jeffrey M Besterman; Zuomei Li
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

Review 10.  Targeted histone deacetylase inhibition for cancer therapy.

Authors:  D M Vigushin; R C Coombes
Journal:  Curr Cancer Drug Targets       Date:  2004-03       Impact factor: 3.428
View more
  1 in total

1.  Synthesis of brominated 2-phenitidine derivatives as valuable inhibitors of cholinesterases for the treatment of Alzheimer's disease.

Authors:  Muhammad Athar Abbasi; Amna Saeed; Khalid Mohmmed Khan; Muhammad Ashraf; Syeda Abida Ejaz
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.